ST Pharm Co Ltd

The company's capital structure is characterized by a debt-to-equity ratio of 0.37, indicating a relatively conservative leverage position. However, the free cash flow is negative at -11,189,329,440 KRW, and capital expenditures are substantial at -30,991,690,400 KRW, suggesting ongoing investment in operations. The current ratio of 4.25 implies strong short-term liquidity, but the negative net cash position after subtracting total debt raises concerns about long-term liquidity.

Profitability metrics are weak, with a return on equity of 0.24% and a return on assets of 0.15%. These figures fall below the typical thresholds for pharmaceutical firms, which often aim for ROE above 10% and ROA above 5%. The operating loss of -3,058,878,990 KRW contrasts with a net income of 1,010,662,010 KRW, indicating that non-operating gains or cost reductions are offsetting operational underperformance.

Geographic and segment exposure is not explicitly detailed in the available data, but the company's primary operations are concentrated in South Korea. This concentration may expose the firm to domestic regulatory and economic risks, which are not fully mitigated by the current capital structure.

Growth trajectory appears mixed. While the company is investing heavily in capital expenditures, the operating loss and weak profitability suggest that these investments have not yet translated into improved performance. Analysts have provided a mean price target of 196,090.91 KRW and a median of 200,000.00 KRW, with a mean recommendation of 1.50, indicating a generally positive outlook despite current financial challenges.

Risk factors include medium liquidity risk due to the negative net cash position and the high capital expenditures. The dilution risk is assessed as low, but the company's reliance on non-operating income to maintain profitability introduces uncertainty. The risk assessment also highlights the need for careful monitoring of cash flow and debt management.

Recent events include the publication of the latest financial data, which shows a net income despite an operating loss. This suggests that the company is managing to maintain profitability through non-operating activities. No recent filings or transcripts have been provided that detail specific strategic changes or new product launches.

There are no material changes, watcher signals, or cross-source signals to report for ST Pharm Co Ltd (237690.KQ). The data indicates this is the first analysis for this ticker, meaning there is no prior basis for computing deltas or identifying recent shifts in market activity. Consequently, no specific events, financial updates, or strategic developments can be synthesized from the provided facts. The absence of analyst coverage, index membership, and top holder data further limits the context available for a traditional financial narrative. The company profile lists one officer, but without accompanying details on leadership changes or corporate actions, no significance can be attributed to this count. Similarly, the lack of sentiment data or dispatch counts over the observed period precludes any assessment of market mood or news flow. In summary, the current dataset for ST Pharm Co Ltd is insufficient to generate a meaningful cross-section synthesis. Investors should await subsequent data updates that may provide the necessary basis for analysis.

Net income surged 58.4% year-over-year to KRW 55 billion in FY2026, demonstrating strong top-line and bottom-line momentum.

Operating income nearly doubled with a 99.5% year-over-year increase, signaling significant improvement in core operational profitability.

Free cash flow turned positive at KRW 27 billion in FY2026, reversing previous deficits and improving liquidity position.

Analysts assign a strong buy recommendation with a mean price target implying 41.5% upside from current levels.

Long-term debt decreased to KRW 78.7 billion in FY2026, reducing leverage and strengthening the balance sheet structure.

Return on invested capital is negative at -0.52%, indicating the company fails to generate adequate returns on its capital base.

Revenue KRW 66.96B, +27,7% YoY; Operating income +1 024,7% YoY.

• ▍Revenue KRW 66.96B, +27,7% YoY
• ▍Operating income +1 024,7% YoY
• ▍Net income +1 343,2% YoY
• ▍Free cash flow +209,0% YoY
• ▍Net margin 22.5%

Revenue KRW 129.10B, +11,6% YoY; Operating income +15,3% YoY.

• ▍Revenue KRW 129.10B, +11,6% YoY
• ▍Operating income +15,3% YoY
• ▍Net income +140,8% YoY
• ▍Free cash flow +310,2% YoY
• ▍Net margin 24.0%

Revenue KRW 81.91B, +32,8% YoY; Operating income +141,6% YoY.

• ▍Revenue KRW 81.91B, +32,8% YoY
• ▍Operating income +141,6% YoY
• ▍Net income +20,2% YoY
• ▍Free cash flow +236,5% YoY
• ▍Net margin 21.5%

Revenue KRW 68.25B, +53,1% YoY; Operating income +522,3% YoY.

• ▍Revenue KRW 68.25B, +53,1% YoY
• ▍Operating income +522,3% YoY
• ▍Net income +436,8% YoY
• ▍Free cash flow +153,5% YoY
• ▍Net margin 7.9%

Revenue KRW 52.42B; Operating income KRW 1.03B.

• ▍Revenue KRW 52.42B
• ▍Operating income KRW 1.03B
• ▍Net margin 2.0%

Revenue KRW 115.74B; Operating income KRW 22.78B.

• ▍Revenue KRW 115.74B
• ▍Operating income KRW 22.78B
• ▍Net margin 11.1%

Revenue KRW 61.70B; Operating income KRW 6.10B.

• ▍Revenue KRW 61.70B
• ▍Operating income KRW 6.10B
• ▍Net margin 23.7%

Revenue KRW 44.59B; Operating income -KRW 3.06B.

• ▍Revenue KRW 44.59B
• ▍Operating income -KRW 3.06B
• ▍Net margin 2.3%

Revenue KRW 331.68B, +21,2% YoY; Operating income +99,5% YoY.

• ▍Revenue KRW 331.68B, +21,2% YoY
• ▍Operating income +99,5% YoY
• ▍Net income +58,4% YoY
• ▍Free cash flow +178,3% YoY
• ▍Net margin 16.6%

Revenue KRW 273.75B, −3,9% YoY; Operating income −17,7% YoY.

• ▍Revenue KRW 273.75B, −3,9% YoY
• ▍Operating income −17,7% YoY
• ▍Net income +77,3% YoY
• ▍Free cash flow −181,2% YoY
• ▍Net margin 12.7%

Revenue KRW 284.99B, +14,3% YoY; Operating income +87,4% YoY.

• ▍Revenue KRW 284.99B, +14,3% YoY
• ▍Operating income +87,4% YoY
• ▍Net income +8,8% YoY
• ▍Free cash flow +64,8% YoY
• ▍Net margin 6.9%

Revenue KRW 249.32B, +50,5% YoY; Operating income +220,0% YoY.

• ▍Revenue KRW 249.32B, +50,5% YoY
• ▍Operating income +220,0% YoY
• ▍Net income +443,5% YoY
• ▍Free cash flow −2,4% YoY
• ▍Net margin 7.2%